P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL

Hemasphere · 2022 · PMC9430053

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with either MYD88 or TNFAIP3 mutations had improved median PFS (not reached (NR) vs 11.1 months, p: 0.009, HR: 0.09, 95% CI: 0.02-0.55); patients with KMT2D showed a trend to worse outcomes (PFS: 13.40 months vs NR, p: 0.06, HR 6.5, 95%CI: 1.06-38.76) [Figure 1 a-c].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.